Primary hyperaldosteronism resident survival guide: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 52: | Line 52: | ||
{{familytree | |!| | | |!| | |M01| |M02| |!| | | | |M01= > 35 years consider|M02= < 35 years consider|}} | {{familytree | |!| | | |!| | |M01| |M02| |!| | | | |M01= > 35 years consider|M02= < 35 years consider|}} | ||
{{familytree | |!| | | |!| | |!| | | |!| | | |!| | | |}} | {{familytree | |!| | | |!| | |!| | | |!| | | |!| | | |}} | ||
{{familytree |N01| |N02|-|N03| |N04| |N05| | | |N01=• Glucocorticoid-remediable aldosteronism (GRA) OR Idiopathic hyperaldosteronism:<br>• Pharmacologic therapy|N02= Adrenal Venous Sampling|N03= Adrenal Venous Sampling|N04=Aldosterone Producing Adenoma (APA) or Primary Adrenal Hyperplasia (PAH):<br> Unilateral laproscopic adrenalectomy|N05= Pharmacological therapy|}} | {{familytree |N01| |N02|-|N03| |N04| |N05| | | |N01=• Glucocorticoid-remediable aldosteronism (GRA) OR Idiopathic hyperaldosteronism:<br>• Pharmacologic therapy|N02= No Lateralization with Adrenal Venous Sampling|N03= Lateralization with Adrenal Venous Sampling|N04=Aldosterone Producing Adenoma (APA) or Primary Adrenal Hyperplasia (PAH):<br> Unilateral laproscopic adrenalectomy|N05= Pharmacological therapy|}} |
Revision as of 15:30, 18 July 2017
Template:Primary hyperladosteronism Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]
Overview
Causes
Common Causes
Common causes of Conn's Syndrome may be divided into:
- Adrenal causes:
- Aldosterone-secreting adrenal adenoma (APA-benign tumor, 50-60%)
- Idiopathic hyperaldosteronism (IHA-Bilateral hyperplasia of the adrenal gland, 40-50%)
- Extra-adrenal causes
- Ectopic secretion of aldosterone (Ovaries and Kidneys)
Less Common Causes
- Familial hyperaldosteronism type I (glucocorticoid-remediable aldosteronism [GRA])
- Familial hyperaldosteronism II (the familial occurrence of APA or bilateral idiopathic hyperplasia or both)
- Familial hyperaldosteronism type III (associated with the germline mutation in the KCNJ5 potassium channel)
- Pure aldosterone-producing adrenocortical carcinomas
- Unilateral adrenal hyperplasia
Diagnosis and Treatment
Preferred screening population: • Blood pressure > 160 / 100 particularly (< 50 years) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plasma Renin Activity/Aldosterone Ratio | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Normal or High Renin (Plasma Renin/Aldosterone ratio <10 | Suppressed Renin (Plasma Renin/Aldosterone ratio >20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
•Renin-secreting tumors •Diuretic use •Renovascular hypertension •Coarctation of aorta •Malignant phase hypertension | Urinary aldosterone | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Elevated | Normal | Low | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conn's syndrome (Primary aldosteronism) | Profound K+ depletion | • 17 alpha hydroxylase deficiency • 11 beta hydroxylase deficiency • Liddle's syndrome • Licorice ingestion •Deoxycorticosterone producing tumor | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Do confirmatory tests: •Fludrocortisone supression test (Positive test= Aldosterone > 6 ng / dl and simultaneous PRA levels < than 1.0 ng / ml / hour) OR •Intravenous saline load testing (Positive test= Aldosterone more than 10 ng / dl) OR •Oral sodium loading test (Positive test= 24-hour urinary aldosterone excretion > 12 μg / day OR •Captopril challenge test (Positive test= PAC / PRA > 30, measured two hours after the administration of 25 mg or 50 mg of captopril) | Add Mineralocrticoid antagonist for 8 weeks | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BP response | No BP response | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subtype classification | • Deoxycorticosterone excess( Tumor, 17 alpha hydroxylase and 11 beta hydroxylase deficiency) • Licorice ingestion •Glucocorticoid resistance | Liddle's syndrome) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adrenal CT scan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Normal, micornodularity, bilateral masses or unilateral atypical mass | Unilateral hypodense nodule >1cm and <2cm in the setting of marked primary hyperaldosteronism | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Surgery not desired | Surgery desired | Surgery desired | Surgery not desired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
> 35 years consider | < 35 years consider | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Glucocorticoid-remediable aldosteronism (GRA) OR Idiopathic hyperaldosteronism: • Pharmacologic therapy | No Lateralization with Adrenal Venous Sampling | Lateralization with Adrenal Venous Sampling | Aldosterone Producing Adenoma (APA) or Primary Adrenal Hyperplasia (PAH): Unilateral laproscopic adrenalectomy | Pharmacological therapy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||